natgillin/translations-raw huggingface dataset:
The 5a-androstane-3β,5,6β-triol for use according to claim 1, wherein the neuron damage is caused by cerebral ischemia. 
a-androstan-3β,5,6β-triol za uporabu u skladu s patentnim zahtjevom 1, pri čemu je oštećenje neurona uzrokovano cerebralnom ishemijom.
The 5a-androstane-3β,5,6β-triol for use according to claim 1, wherein the neuron damage is caused by spinal cord ischemia. 
a-androstan-3β,5,6β-triol za uporabu u skladu s patentnim zahtjevom 1, pri čemu je oštećenje neurona uzrokovano ishemijom leđne moždine.
The 5a-androstane-3β,5,6β-triol for use according to claim 1, wherein the neuron damage is caused by hypoxia. 
a-androstan-3β,5,6β-triol za uporabu u skladu s patentnim zahtjevom 1, pri čemu je oštećenje neurona uzrokovano hipoksijom.
a hull insert (2), or trunk, forming a housing (3), or propeller case, located within a hull (4) of a ship or platform; 
umetak trupa (2), ili sanduk, koji formira kućište (3), ili spremnik propelera, smješten unutar trupa (4) broda ili platforme;
said housing (3) being a housing watertight with respect to the hull in all the walls (5) thereof, except for an opening (6) opening externally to the hull (4) of the ship or platform; 
kućište (3) je nepropusno kućište u odnosu na trup unutar zidova (5), osim otvora (6) koji se otvara izvan trupa (4) broda ili platforme;
said motor (7) being arranged in said hull (4), but externally to said housing (3), and being arranged stationary with respect to said hull (4); 
motor (7) smješten je u trupu (4), ali izvan kućišta (3), i organiziran je stacionarno u odnosu na trup (4);
a thruster (8), for example, a propeller foot; 
potisnik (8), na primjer, noga propelera;
said thruster (8) being suitable to be arranged externally to said hull (4) to generate a propulsion thrust on said ship or floating platform; 
potisnik (8) prikladan je da bude organiziran izvan trupa (4) kako bi se generiralo porivni potisnik na brodu ili plutajućoj platformi;
said thruster (8) being retractable within said housing (3) passing through said opening (6); 
potisnik (8) se može uvući u kućište (3) prolaženjem kroz otvor (6);
a submersible movable hatch (10) in a separate piece and completely disconnectable from said thruster (8) and said housing (3); 
potopni pokretni otvor (10) na odvojenom dijelu koji se može potpuno odvojiti od potisnika (8) i kućišta (3);
The assembly (1) according to any of the preceding claims, wherein said fluid evacuation device (12) is suitable to the reintroduction of fluid into the closed chamber (11), for example, at the end of the maintenance operations; 
Sklop (1) sukladno bilo kojem od prethodnih zahtjeva, pri čemu je uređaj za izbacivanje tekućine (12) prikladan za ponovno uvođenje tekućine u zatvorenu komoru (11), na primjer, na kraju operacije održavanja;
and/or wherein said assembly further comprises an air pumping-in device (16) for introducing air into the closed chamber (11), for example, tubes for the connection of the closed chamber, or propeller case, with the inside of the hull. 
i/ili pri čemu sklop nadalje sadrži uređaj za ubrizgavanje zraka (16) za uvođenje zraka u zatvorenu komoru (11), na primjer, cijevi za spajanje zatvorene komore, ili kućišta propelera, s unutrašnjosti trupa.
The assembly (1) according to any of the preceding claims, wherein said hull insert, or trunk (2), is a structure integrated in the structure of the hull (4). 
Sklop (1) sukladno bilo kojem od prethodnih zahtjeva, pri čemu je umetak za trup, ili sanduk (2), struktura integrirana u strukturu trupa (4).
at least one feeding line (13) of affluent water to at least one containing means (12); 
najmanje jednu liniju napajanja (13) vode koja pritječe do najmanje jednog sredstva za spremanje (12);
at least one chemical application means (6); 
najmanje jedno sredstvo za primjenjivanje kemikalija (6);
at least one coupling means (5) that connects said at least one propelling means (4) to said at least one suction means (3); 
najmanje jedno sredstvo za spajanje (5) koje povezuje navedeno najmanje jedno klizno pokretno sredstvo (4) s navedenim najmanje jednim sredstvom za usisavanje (3);
The system of any preceding claim, wherein the chemical application means (6) comprises an injector, a sprinkler, manual application, a dispenser by weight, piping, or a combination thereof. 
Uređaj iz bilo kojeg od patentnih zahtjeva 7 do 8, pri čemu sredstvo za primjenu kemikalija (6) obuhvaća injektor, raspršivač, dispenzor prema masi, cjevovod, ili njihovu kombinaciju.
The system of any preceding claim, wherein the coupling means (5) comprises a flexible cord, rope, line, cable, string, or a combination thereof. 
Uređaj iz bilo kojeg od patentnih zahtjeva 7 do 10, pri čemu sredstvo za spajanje (5) obuhvaća fleksibilno uže, konop, liniju, kabel, žicu, ili njihovu kombinaciju.
The system of any preceding claim, wherein the coupling means (5) comprises a rigid rod, bar, pole, shaft, or a combination thereof. 
Uređaj iz bilo kojeg od patentnih zahtjeva 7 do 11, pri čemu sredstvo za spajanje (5) obuhvaća krutu letvu, štap, motku, osovinu ili njihovu kombinaciju.
The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein:- 
Spoj iz zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, pri čemu: -
The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, having Formula II. 
Spoj iz bilo kojeg od zahtjeva od 1 do 4, ili njegova farmaceutski prihvatljiva sol, pri čemu:-
Storing said water in at least one containing means (8), where said containing means (8) has a bottom (17) able to be thoroughly cleaned by a mobile suction means (5) and wherein said containing means has a volume of at least 15.000 m3; 
pohrana navedene vode u najmanje jednom sredstvu za spremanje (8) s volumenom od najmanje 15 000 m3, pri čemu navedeno sredstvo za spremanje ima dno (17) koje se može temeljito očistiti mobilnim sredstvom za usisavanje (5);
For water temperatures up to 35 degrees Celsius, maintaining said water's ORP of at least 500 mV for a minimum period of 1 hour for each degree Celsius of water temperature, by adding disinfectant agents to the water; 
za vodu temperature do 35°C, održavanje ORP-a navedene vode najmanje na 500 mV kroz najmanje razdoblje od 1 sata za svaki °C temperature vode;
For water temperatures greater than 35 degrees Celsius and up to 69 degrees Celsius, maintaining said water's ORP of at least 500 mV for a minimum period of hours by adding disinfectant agents to the water, wherein the minimum period of hours is calculated by the following equation: [35 hours] - [Temperature of the water in degrees Celsius - 35] = minimum period of hours; and 
za vodu temperature veće od 35°C i do 69°C, održavanje ORP-a navedene vode od najmanje 500 mV kroz najmanje razdoblje u satima, pri čemu je najmanje razdoblje u satima izračunato sljedećom jednadžbom: [35 sati] - [temperatura vode u °C - 35] = najmanje razdoblje u satima; i
Method for treating water at low cost, according to claim 1, wherein the information received by the coordination means is obtained by visual inspection, algorithms based on experience, by electronic detectors, or combinations thereof. 
Metoda niskih troškova za tretiranje vode, u skladu s bilo kojim od patentnih zahtjeva 1 do 6, pri čemu su informacije koje prima sredstvo upravljanja (1) dobivene vizualnim pregledom, algoritmima na bazi iskustva, elektroničkim detektorima ili njihovim kombinacijama.
The compound for use of claim 1, or a pharmaceutically acceptable salt thereof, wherein:- 
Spoj iz zahtjeva 1, ili njegova farmaceutski prihvatljiva sol, pri čemu: -
The compound for use of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein:- 
Spoj iz bilo kojeg od zahtjeva od 1 do 3, ili njegova farmaceutski prihvatljiva sol, pri čemu su:-
The compound for use of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein:- 
Spoj iz bilo kojeg od zahtjeva od 1 do 4, ili njegova farmaceutski prihvatljiva sol, pri čemu:-
The compound for use of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein R15 is H or 5-10 membered heteroaryl optionally substituted by C1-6 alkyl. 
Spoj iz bilo kojeg od zahtjeva od 1 do 5, ili njegova farmaceutski prihvatljiva sol, pri čemu je R15 H ili 5-10-člani heteroaril opcionalno suptituiran C1-6alkilom.
The compound for use of claim 8, or a pharmaceutically acceptable salt thereof, wherein R4 is halo, R5 is methoxy, R6 is H, R7 is methoxy, and R8 is halo. 
[image] Spoj iz zahtjeva 8, ili njegova farmaceutski prihvatljiva sol, pri čemu je R4 halo, R5 je metoksi, R6 je H, R7 je metoksi i R8 je halo.
The compound for use of claim 8 or 9, or a pharmaceutically acceptable salt thereof, wherein R9 is C1-6 alkyl. 
Spoj iz zahtjeva 8 ili 9, ili njegova farmaceutski prihvatljiva sol, pri čemu R9 je C1-6alkil.
The compound for use of claim 1, selected from: 
Spoj iz zahtjeva 1 koje je izabrano od:
The use of any of claims 1 to 8, characterized in that said lipochitooligosaccharide of formula (I) is used at a concentration of 10-5 to 10-12 M. 
Uporaba iz bilo kojeg od patentnih zahtjeva 3 do 5, karakterizirana na način da se navedena smjesa lipokitooligosaharida koristi u koncentraciji od 10-5 do 10-12 M.
A pharmaceutical composition for use according to claim 1, wherein said pharmaceutical composition consists of 50 mg/mL of SEQ ID NO: 1, sodium phosphate, trehalose, mannitol, polysorbate 80 and water and is maintained at pH 7.2. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se navedeni farmaceutski pripravak sastoji od 50 mg/ml SEQ ID NO: 1, natrijevog fosfata, trehaloze, manitola, polisorbata 80 i vode i održava se na pH 7,2.
A pharmaceutical composition for use according to any one of claims 1 to 3 for use in the treatment of diabetes, hyperglycemia, type II diabetes, or at least one cardiovascular disorder. 
Farmaceutski pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je namijenjen upotrebi u liječenju dijabetesa, hiperglikemije, dijabetesa tip II ili najmanje jednog kardiovaskularnog poremećaja.
A pharmaceutical composition for use according to claim 6, wherein administration is via subcutaneous injection selected from the group of at least one 0.32 mL injection, at least one 0.65 mL injection, and at least one 1.0 mL injection. 
Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 6, naznačen time što se primjena vrši supkutanom injekcijom koja se bira iz skupine koju čine najmanje jedna injekcija 0,32 ml, najmanje jedna injekcija 0,65 ml i najmanje jedna injekcija 1,0 ml.
A pharmaceutical composition for use according to any one of claims 1 to 7, wherein said pharmaceutical composition is co-administered with a compound selected from: a second GLP-1 agonist, incretin hormone, incretin mimetic, agent to increase insulin secretion, sulfonylurea, meglitinide, acetohexamide, chlorpropamide, tolazamide, glipizide, gliclazide, glibenclamide (glyburide), gliquidone, glimepiride, agent to inhibit GLP-1 break down, DPP-IV inhibitor, agent to increase glucose utilization, glitazone, thiazolidinedione, rosiglitazone, pioglitazone, pPAR agonist, agent to reduce hepatic glucose production, metformin, agent to delay glucose absorption, a-glucosidase inhibitor, insulin glargine and/or insulin. 
Farmaceutski pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što se navedeni farmaceutski pripravak suprimijenjuje sa spojem kojeg se bira između: drugog agonista GLP-1, hormona inkretina, inkretinomimetika, sredstva za pojačanje izlučivanja inzulina, sulfoniluree, meglitinida, acetoheksamida, klorpropamida, tolazamida, glipizida, gliklazida, glibenklamida (gliburida), glikvidona, glimepirida, sredstva za inhibiranje razgradnje GLP-1, inhibitora DPP-IV, sredstva za pojačanje iskorištavanja glukoze, glitazona, tiazolidindiona, roziglitazona, pioglitazona, agonista pPAR, sredstva za smanjivanje proizvodnje glukoze u jetri, metformin, sredstva za odgađanje apsorpcije glukoze, inhibitora a-glukozidaze, inzulin-glargina i/ili inzulina.
The monoclonal antibody of any one of claims 8 to 10, which is a humanized antibody or a human antibody. 
Monoklonsko protutijelo u skladu s patentnim zahtjevom 10 ili 11, naznačen time, da je humanizirano protutijelo ili ljudsko protutijelo.
The monoclonal antibody of claim 17 for use in improving outcomes in orthopedic procedures, dental procedures, implant surgery, joint replacement, bone grafting, bone cosmetic surgery or bone repair such as fracture healing, nonunion healing, delayed union healing or facial reconstruction. 
Monoklonsko protutijelo prema bilo kojem od patentnih zahtjeva 10 do 17, naznačeno time, da se koristi u postupku poboljšanja ishoda kod ortopedskih zahvata, dentalnih zahvata, operacija usadka, zamjene zgloba, presađivanja kosti, kozmetičke operacije kosti i reparacije poput liječenja lomova, zacjeljivanja bez srastanja, zakašnjelog zacjeljivanja bez srastanja ili rekonstrukcije lica.
Apparatus as in claim 4, characterized in that it comprises a pressing roll (27) cooperating, during use, with said finishing roll (26) and selectively movable in a direction orthogonal to the direction of advance (D). 
Uređaj prema zahtjevu 4, naznačen time da sadrži pritisni valjak (27) koji, tijekom rada, surađuje s navedenim završnim valjkom (26) i selektivno je pomičan u smjeru pod pravim kutom na smjer napredovanja (D).
Method as in claim 7, characterized in that said metal wire (F) passes first through said straightening only unit (11) and then through said drawing unit (12). 
Postupak prema zahtjevu 7, naznačen time da navedena metalna žica (F) prvo prolazi kroz navedenu jedinicu samo za izravnavanje (11) i zatim kroz navedenu jedinicu za izvlačenje (12).
or R6 and R6 both attached to the same carbon ring atom form, together with the carbon ring atom to which they are attached, a -(C=O)- group; 
ili R6 i R6 oba vezana za isti oblik ugljikovog atoma u prstenu, zajedno s ugljikovim atomom u prstenu za kojeg su vezani, -(C=O)- skupina;
is aryl, wherein said aryl is substituted with 1 substituent R6; 
je aril, gdje je rečeni aril supstituiran s 1 supstituentom R6;
A compound according to claim 7, wherein R1 is (C2-C6)alkenyl. 
Spoj u skladu s patentnim zahtjevom 7, naznačen time, da R1 je (C2-C6)alkenil.
A compound according to claim 1, wherein the compound is (E)-2-(3,3-dimethylbut-1-enyl)-4,5-dihydroxyisophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj (E)-2-(3,3-dimetilbut-1-enil)-4,5- dihidroksi izoftalo nitril.
A compound according to claim 1, wherein the compound is (E)-4,5-dihydroxy-2-(prop-1-enyl)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj (E)-4,5-dihidroksi-2-(prop-1-enil)izoftalonitril.
A compound according to claim 1, wherein the compound is 4'-ethyl-3,4-dihydroxybiphenyl-2,6-dicarbonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4'-etil-3,4-dihidroksibifenil-2,6-dikarbonitril.
A compound according to claim 1, wherein the compound is 4,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4,5-dihidroksi-2-(4-metilbenzil)izoftalonitril.
A compound according to claim 1, wherein the compound is 4,5-dihydroxy-2-(2-methoxybenzyl)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4,5-dihidroksi-2-(2-metoksibenzil)izoftalonitril.
A compound according to claim 1, wherein the compound is 2-(3,5-dimethylbenzyl)-4,5-dihydroxyisophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 2-(3,5-dimetilbenzil)-4,5-dihidroksiizoftalonitril.
A compound according to claim 1, wherein the compound is 2-(2-ethylbenzyl)-4,5-dihydroxyisophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 2-(2-etilbenzil)-4,5-dihidroksiizoftalonitril.
A compound according to claim 1, wherein the compound is 4,5-dihydroxy-2-(2-methylprop-1-enyl)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4,5-dihidroksi-2-(2-metilprop-1-enil)izoftalonitril.
A compound according to claim 1, wherein the compound is 4,5-dihydroxy-2-(prop-1-en-2-yl)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4,5-dihidroksi-2-(prop-1-en-2-il)izoftalonitril.
A compound according to claim 1, wherein the compound is 2-(2-ethoxythiazol-5-yl)-4,5-dihydroxyisophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 2-(2-etoksitiazol-5-il)-4,5-dihidroksiizoftalonitril.
A compound according to claim 1, wherein the compound is 3,4-dihydroxy-4'-propylbiphenyl-2,6-dicarbonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 3,4-dihidroksi-4'-proplbifenil-2,6-dikarbonitril.
A compound according to claim 1, wherein the compound is 2-(4-ethylphenylthio)-4,5-dihydroxyisophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 2-(4-etilfeniltio)-4,5-dihidroksiizoftalonitril.
A compound according to claim 1, wherein the compound is 4,5-dihydroxy-2-(4-methoxyphenylthio)isophthalonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 4,5-dihidroksi-2-(4-metoksifeniltio)izoftalonitril.
A compound according to claim 1, wherein the compound is 3,4-dihydroxy-4'-methoxybiphenyl-2,6-dicarbonitrile. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je spoj 3,4-dihidroksi-4'-metoksibifenil-2,6-dikarbonitril.
A compound according to claim 44, wherein the disease is Parkinson's disease. 
Spoj u skladu s patentnim zahtjevom 44, naznačen time, da je bolest Parkinsonova bolest.
A method for stabilization of micronized or milled solvates of tiotropium bromide, selected from solvates with methanol, ethanol, 2-propanol, 1,2-propanediol, 1,3-propanediol, n-butanol, 1,4-butandiol and tert -butanol, characterized in that the solvates are deposited in a saturated atmosphere of the adequate solvent for the time period sufficient for recovery of solvent. 
Postupak za stabilizaciju mikroniziranih ili mljevenih solvata tiotropij bromida, odabranih od solvata s metanolom, etanolom, 2-propanolom, 1,2-propanediolom, 1,3-propanediolom, n-butanolom, 1,4-butandiolom i terc-butanolom, naznačen time, da su solvati pohranjeni u zasićenoj atmosferi odgovarajućeg otapala za vremensko razdoblje koje je dovoljno za oporavak otapala.
The method according to claim 1, characterized in that said solvates are deposited in close container where vacuum is applied to achieve saturated atmosphere of the adequate solvent. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da su rečeni solvati pohranjeni u zatvorenoj posudi uz primjenu vakuuma kako bi se postigla zasićena atmosfera odgovarajućeg otapala.
Tiotropium bromide solvate according to claim 4, which has a powder X-ray diffraction spectrum having the main peaks (+/-0,2° 2Theta) 11,0; 15,3; 18,0; 21,4; 25,0, measured using CuKa. 
Solvat tiotropij bromida u skladu s patentnim zahtjevom 4, naznačen time, da rendgenskim difraktogramom ima glavne maksimume (+1-0,2° 2Theta) 11,0; 15,3; 18,0; 21,4; 25,0, mjerene uporabom CuKa.
Tiotropium bromide solvate according to claim 5, which has a powder X-ray diffraction spectrum having the other characteristic peaks (+/-0,2° 2Theta) 9,9; 13,4; 16,3; 19,8; 20,9; 23,5; 23,9; 24,6; 25,8; 26,0; 27,0; 27,8; 31,8. 
Solvat tiotropij bromida u skladu s patentnim zahtjevom 5, naznačen time, da rendgenskim difraktogramom ima glavne druge karakteristične maksimume (+1-0,2° 2Theta) 9,9; 13,4; 16,3; 19,8; 20,9; 23,5; 23,9; 24,6; 25,8; 26,0; 27,0; 27,8; 31,8.
or a pharmaceutically acceptable salt, enantiomer, diastereomer, geometric isomer or solvate thereof. 
ili njegova farmaceutski prihvatljiva sol, enantiomer, dijastereomer, geometrijski izomer ili solvat.
Compound according to claim 1 wherein R2 and R4 are independently selected from the group consisting of hydrogen, halogen, trifluoromethyl and C1-4alkoxy 
Spoj u skladu s patentnim zahtjevom 1 naznačen time što se R2 i R4 neovisno bira iz skupine koju čine vodik, halogen, trifluormetil i C1-4alkoksi.
identifying or determining the carbohydrates and/or the carbohydrate mixture composition patterns wherein the standard composition is added to the sample containing the unknown carbohydrate mixture composition, and wherein the standard of known composition is a known carbohydrate mixture composition. 
identifikacija ili određivanje ugljikohidrata i/ili uzoraka sastava ugljikohidratne smjese pri čemu se standardni sastav dodaje uzorku koji sadrži nepoznati sastav smjese ugljikohidrata i pri čemu standard poznatog sastava jest poznati sastav smjese ugljikohidrata.
comparing the standard migration time indices calculated from the obtained electropherogram of the first sample and the second sample; 
usporedba indeksa standardnih vremena migracije izračunatih iz dobivenog elektroferograma prvog uzorka i drugog uzorka;
analysing the identity and/or differences between the carbohydrate mixture composition pattern profiles of the first and the second sample wherein standard migration time indices of the carbohydrates present in the samples are calculated based on internal standards of known composition whereby the internal standard is added to the samples to be analysed, and wherein the standard is a known carbohydrate mixture composition. 
analiza identiteta i/ili razlika između profila obrasca sastava ugljikohidratne smjese prvog i drugog uzorka; pri čemu se indeksi standardnog vremena migracije ugljikohidrata prisutnog u uzorku izračunavaju na temelju unutarnjih standarda poznatog sastava, pri čemu se unutarnji standard dodaje u uzorke koji se analiziraju i pri čemu je standard poznati sastav ugljikohidratne smjese.
The method according to anyone of the preceding claims, wherein the standard is a known glycan pool. 
Metoda u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je standard poznati uzorak glikana.
A compound according to claim 1 which is 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]furo[3,4-b]pyridin-5(7H)-one or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]furo[3,4-b]piridin-5(7H)-on ili njegova farmaceutski prihvatljiva sol.
A compound according to claim 5 which is a pharmaceutically acceptable salt of 4-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]furo[3,4-b]pyridin-5(7H)-one. 
Spoj u skladu s patentnim zahtjevom 5, naznačen time što je farmaceutski prihvatljiva sol of 4-[3-(4-fluorfenil)-1-metil-1H-pirazol-4-il]furo[3,4-b]piridin-5(7H)-on.
A compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt thereof for use in treating a sleep, a neurological or a psychiatric disease or disorder in a mammal. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju poremećaja spavanja, te neurološke ili psihijatrijske bolesti ili poremećaja kod sisavca.
A compound for use according to claim 8 wherein the disease or disorder is a mood disorder or a sleep disorder. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 8, naznačen time što je bolest ili poremećaj poremećaj raspoloženja ili poremećaj spavanja.
A compound for use according to claim 9 wherein the mood disorder is selected from the group consisting of a depressive disorder and a bipolar disorder. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 9, naznačen time što se poremećaj raspoloženja bira iz skupine koju čine depresivni poremećaj i bipolarni poremećaj.
A compound for use according to claim 11 wherein the disease or disorder is Alzheimer's disease. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 11, naznačen time što je bolest ili poremećaj Alzheimerova bolest.